CanSino Biologics Inc. announced that, as proposed by the National Health Commission of the People's Republic of China and approved by the National Medical Products Administration of the People's Republic of China upon demonstration, the Recombinant COVID-19 XBB.1.5 Variant Vaccine for Inhalation (Adenovirus Type 5 Vector) (the " Recombinant COVID-19 XBB.1.5 Variant Vaccine for Inhalation") developed by the Company has been included for emergency use. Convidecia Air®, as the first global COVID-19 vaccine for inhalation, can not only stimulate humoral and cellular immunity, but also induce mucosal immunity to achieve triple comprehensive protection efficiently without intramuscular injection. The Recombinant COVID-19 XBB.1.5 Variant Vaccine for Inhalation will contribute to the renewal of immunization strategies and provide better protection to the population.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.82 HKD | +2.51% | +14.06% | -20.08% |
Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.08% | 1.1B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 6185 Stock
- News CanSino Biologics Inc.
- CanSino Biologics Inc. announces Recombinant Covid-19 Xbb.1.5 Variant Vaccine Forinhalation (Adenovirus Type 5 Vector) Included for Emergency Use